Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

Company Overview

Pasithea Therapeutics, Inc. (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders. Pasithea’s research approach centers on human-derived antibodies with tailored specificity and functionality, addressing areas of high unmet need such as severe chronic inflammatory conditions. By applying its platform to a range of targets, Pasithea seeks to advance innovative therapies toward regulatory milestones and strategic partnerships.

Headquartered in Seattle, Washington, Pasithea Therapeutics maintains research and development operations in the Pacific Northwest, with teams dedicated to antibody engineering, translational science and regulatory strategy. The company is led by a management team with experience in biotechnology innovation, clinical development and commercialization, supported by a board of directors and scientific advisors drawn from leading academic and industry institutions. Pasithea continues to explore collaborations with academic centers and pharmaceutical partners to accelerate its therapeutic programs.

Key Stats

• Today's Range: $0.75 to $0.79
• 50-Day Range: $0.68 to $0.90
• 52-Week Range: $0.65 to $4.78
• Volume: 19,693 shs
• Average Volume: 2.40 million shs
• Market Capitalization: $5.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Pasithea Therapeutics Stock Analysis - MarketRank™

Pasithea Therapeutics scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Pasithea Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pasithea Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pasithea Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pasithea Therapeutics has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.82% of the float of Pasithea Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Pasithea Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pasithea Therapeutics has recently decreased by 44.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pasithea Therapeutics does not currently pay a dividend.

Dividend Growth

Pasithea Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.82% of the float of Pasithea Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Pasithea Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pasithea Therapeutics has recently decreased by 44.11%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: N/A

News Sentiment

Pasithea Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Pasithea Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for KTTA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Pasithea Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.70% of the stock of Pasithea Therapeutics is held by insiders.

Percentage Held by Institutions

Only 23.92% of the stock of Pasithea Therapeutics is held by institutions.

KTTA Stock Analysis - Frequently Asked Questions

How have KTTA shares performed this year?

Pasithea Therapeutics' stock was trading at $3.15 at the beginning of the year. Since then, KTTA shares have decreased by 74.9% and is now trading at $0.79.

How were Pasithea Therapeutics' earnings last quarter?

Pasithea Therapeutics Corp. (NASDAQ:KTTA) released its quarterly earnings results on Thursday, August, 14th. The company reported ($0.66) EPS for the quarter.

When did Pasithea Therapeutics' stock split?

Shares of Pasithea Therapeutics reverse split before market open on Tuesday, January 2nd 2024.The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Pasithea Therapeutics IPO?

Pasithea Therapeutics (KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

How do I buy shares of Pasithea Therapeutics?

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pasithea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), Meta Platforms (META), Plug Power (PLUG), QuantumScape (QS), Airbnb (ABNB), Advanced Micro Devices (AMD) and Ginkgo Bioworks (DNA).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/09/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KTTA
• CIK: 1841330
• Web: www.pasithea.com
• Phone: 702-514-4174
• Fax: N/A
• Employees: 3
• Year Founded: 2020

Profitability

• EPS (Trailing Twelve Months): ($7.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.90 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -88.60%
• Return on Assets: -81.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.97
• Quick Ratio: 4.97

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.60 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 7,440,000
• Free Float: 7,243,000
• Market Cap: $5.88 million
• Optionable: Not Optionable
• Beta: 0.27